Journal
JOURNAL OF NEUROSCIENCE
Volume 29, Issue 6, Pages 1846-1854Publisher
SOC NEUROSCIENCE
DOI: 10.1523/JNEUROSCI.5715-08.2009
Keywords
Alzheimer's disease; amyloid beta; transgenic; immunity; behavior; antibody; histochemistry
Categories
Funding
- National Institutes of Health [AG20245, AG15408]
- Alzheimer's Association/Stranahan Foundation [IIRG-06-26434, NIRG-04-1162]
Ask authors/readers for more resources
The pathogenesis of Alzheimer's disease (AD) is thought to be related to the accumulation of amyloid beta (A beta) in amyloid deposits and toxic oligomeric species. Immunomodulation is emerging as an effective means of shifting the equilibrium from A beta accumulation to clearance; however, excessive cell mediated inflammation and cerebral microhemorrhages are two forms of toxicity which can occur with this approach. Vaccination studies have so far mainly targeted the adaptive immune system. In the present study, we have stimulated the innate immune system via the Toll-like receptor 9 (TLR9) with cytosine-guanosine-containing DNA oligodeoxynucleotides in Tg2576 AD model transgenic mice. This treatment produced a 66% and 80% reduction in the cortical (p = 0.0001) and vascular (p = 0.0039) amyloid burden, respectively, compared with nontreated AD mice. This was in association with significant reductions in A beta 42, A beta 40, and A beta oligomer levels. We also show that treated Tg mice performed similarly to wild-type mice on a radial arm maze. Our data suggest that stimulation of innate immunity via TLR9 is highly effective at reducing the parenchymal and vascular amyloid burden, along with A beta oligomers, without apparent toxicity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available